Curcumin Effect on MMPs and TIMPs genes in a breast cancer cell line

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3259-3264

  Hassan, Zeinab Korany ^a,b   Daghestani, Maha Hassan ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Curcumin; Matrix metalloproteinases; Tissue inhibitor of metalloproteinases

Indexed keywords

EID: 84873586059     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3259     Document Type: Article

References (60)

1. Aggarwal B B, Banerjee S, Bharadwaj U, et al. (2007). Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclindependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol, 73, 1024-32.
2. Baker E A, Bergin F G, Leaper D J. (2000). Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg, 87, 1215-21.
3. Baker E A, Stephenson T J, Reed M W, Brown N J. (2002). Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol, 55, 300-4.
4. Bica C G, Da Silva L L, Toscani N V, et al. (2010). Polymorphism (ALA16VAL) correlates with regional lymph node status in breast cancer. Cancer Genet Cytogenet, 196, 153-8.
5. Brummer O, Athar S, Riethdorf L, et al. (1999). Matrixmetalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch, 435, 566-73.
6. Buck T B, Yoshiji H, Harris S R, Bunce O R, Thorgeirsson U P. (1999). The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice. Ann N Y Acad Sci, 878, 732-5.
7. Chen A, Xu J, Johnson A C. (2006). Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene, 25, 278-87.
8. Chirco R, Liu X W, Jung K K, Kim H R. (2006). Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev, 25, 99-113.
9. Choudhuri T, Pal S, Das T, Sa G. (2005). Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem, 280, 20059-68.
10. Curran S, Dundas S R, Buxton J, et al. (2004). Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res, 10, 8229-34.
11. Decock J, Hendrickx W, Drijkoningen M, et al. (2007). Matrix metalloproteinase expression patterns in luminal A type breast carcinomas. Dis Markers, 23, 189-96.
12. Dorai T, Dutcher J P, Dempster D W, Wiernik P H. (2004). Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate, 60, 1-17.
13. Figueira R C, Gomes L R, Neto J S, et al. (2009). Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer, 9, 20.
14. Finan K M, Hodge G, Reynolds A M, et al. (2006). In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung Cancer, 53, 273-84.
15. Forget M A, Desrosiers R R, Beliveau R. (1999). Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol, 77, 465-80.
16. Gao W, Chan J Y, Wei W I, Wong T S. (2012). Anti-Cancer Effects of Curcumin On Head And Neck Cancers. Anticancer Agents Med Chem.
17. Huang M T, Lou Y R, Ma W, et al. (1994). Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res, 54, 5841-7.
18. Iwasaki M, Nishikawa A, Fujimoto T, et al. (2002). Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol, 85, 103-7.
19. Jiang Y, Goldberg I D, Shi Y E. (2002). Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene, 21, 2245-52.
20. John A, Tuszynski G. (2001). The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res, 7, 14-23.
21. Kato Y, Yamashita T, Ishikawa M. (2002). Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep, 9, 565-9.
22. Khokha R. (1994). Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst, 86, 299-304.
23. Kim H J, Park C I, Park B W, Lee H D, Jung W H. (2006). Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J, 47, 333-42.
24. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. (2009). Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer, 9, 188.
25. Kotzsch M, Farthmann J, Meye A, et al. (2005). Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer, 41, 2760-8.
26. Kunnumakkara A B, Anand P, Aggarwal B B. (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett, 269, 199-225.
27. Lee C W, Lin W N, Lin C C, et al. (2006). Transcriptional regulation of VCAM-1 expression by tumor necrosis factoralpha in human tracheal smooth muscle cells: involvement of MAPKs, NF-kappaB, p300, and histone acetylation. J Cell Physiol, 207, 174-86.
28. Li H C, Cao D C, Liu Y, et al. (2004). Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat, 88, 75-85.
29. Lin L, Wang P, Zhao X L. (2012). Study on curcumin-induced apoptosis in ovarian cancer resistant cell lines COC1/DDP. Sichuan Da Xue Xue Bao Yi Xue Ban, 43, 335-9 (in Chinese).
30. Maheshwari R K, Singh A K, Gaddipati J, Srimal R C. (2006). Multiple biological activities of curcumin: a short review. Life Sci, 78, 2081-7.
31. Mannello F, Luchetti F, Falcieri E, Papa S. (2005). Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis, 10, 19-24.
32. Martin D C, Ruther U, Sanchez-Sweatman O H, Orr F W, Khokha R. (1996). Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene, 13, 569-76.
33. Montgomery A M, Mueller B M, Reisfeld R A, Taylor S M, DeClerck Y A. (1994). Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res, 54, 5467-73.
34. Munshi H G, Wu Y I, Mukhopadhyay S, et al. (2004). Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem, 279, 39042-50.
35. Mylona E, Magkou C, Giannopoulou I, et al. (2006). Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome. Breast Cancer Res, 8, 57.
36. Nagaraju G P, Aliya S, Zafar S F, et al. (2012). The impact of curcumin on breast cancer. Integr Biol, (in press).
37. Nagase H, Visse R, Murphy G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res, 69, 562-73.
38. Notoya M, Nishimura H, Woo J T, et al. (2006). Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. Eur J Pharmacol, 534, 55-62.
39. Overall C M, Lopez-Otin C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer, 2, 657-72.
40. Pacheco M M, Mourao M, Mantovani E B, Nishimoto I N, Brentani M M. (1998). Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis, 16, 577-85.
41. Park J, Conteas CN. Anti-carcinogenic properties of curcumin on colorectal cancer. World J Gastrointest Oncol, 2, 169-76.
42. Park M J, Kim E H, Park I C, et al. (2002). Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclindependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol, 21, 379-83.
43. Perkins S, Verschoyle R D, Hill K, et al. (2002). Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev, 11, 535-40.
44. Philip S, Bulbule A, Kundu G C. (2004). Matrix metalloproteinase-2: mechanism and regulation of NFkappaB-mediated activation and its role in cell motility and ECM-invasion. Glycoconj J, 21, 429-41.
45. Przybylowska K, Kluczna A, Zadrozny M, et al. (2006). Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat, 95, 65-72.
46. Pulukuri S M, Patibandla S, Patel J, Estes N, Rao J S. (2007). Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene, 26, 5229-37.
47. Qi JH, Ebrahem Q, Moore N, et al. (2003). A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med, 9, 407-15.
48. Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J. (2012). Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol, 29, 561-9.
49. Ree A H, Florenes V A, Berg J P, et al. (1997). High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res, 3, 1623-8.
50. Shishodia S, Chaturvedi M M, Aggarwal B B. (2007). Role of curcumin in cancer therapy. Curr Probl Cancer, 31, 243-305.
51. Sintara K, Thong-Ngam D, Patumraj S, Klaikeaw N. (2012). Curcumin attenuates gastric cancer induced by N-methyl-Nnitrosourea and saturated sodium chloride in rats. J Biomed Biotechnol, 915380.
52. Stetler-Stevenson W G. (2008). The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2. Cancer Metastasis Rev, 27, 57-66.
53. Stetler-Stevenson W G, Seo D W. (2005). TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med, 11, 97-103.
54. Sun J. (2010). Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells. J Signal Transuct.
55. Valente P, Fassina G, Melchiori A, et al. (1998). TIMP-2 overexpression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer, 75, 246-53.
56. Vizoso F J, Gonzalez L O, Corte M D, et al. (2007). Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer, 96, 903-11.
57. Woo MS, Jung SH, Kim SY, et al. (2005). Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun, 335, 1017-25.
58. Yang CL, Liu YY, Ma YG, et al. (2012). Curcumin Blocks Small Cell Lung Cancer Cells Migration, Invasion, Angiogenesis, Cell Cycle and Neoplasia through Janus Kinase-STAT3 Signalling Pathway. PLoS One, 7, 37960.
59. Zhang YG, Du J, Tian XX, Zhong YF, Fang WG. (2007). Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas. Chin Med J, 120, 1597-605.
60. Zheng S, Chen A. (2004). Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J, 384, 149-57.